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involvement of these ephrin members on the catabolic/anabolic
activities of human OA chondrocytes. More speciﬁcally, we looked
at the expression level and production of EphB4 receptor and
ephrin B2, the activation of EphB4 receptor by ephrin B2 on the
modulation of cartilage catabolic/anabolic mediators in the pres-
ence/absence of IL-1β, as well as the intra-cellular signaling path-
ways employed following EphB4 receptor activation. We further
investigated factors that could modulate these ephrin members on
OA chondrocytes.
Methods: EphB4 receptor and ephrin B2 expression levels and
modulation were analyzed by quantitative-PCR and their produc-
tion by immunohistochemistry. The functional consequences of the
ephrin B2-mediated EphB4 receptor activation were investigated
by determining the production of some factors involved in the OA
process, including IL-1β, IL-6, MMP-1, MMP-2, MMP-9, MMP-13,
collagen type II and the receptor PAR-2.
Results: The EphB4 receptor and ephrin B2 ligand are expressed
by human normal and OA chondrocytes. Ephrin B2 is produced
at similar levels and localized at the superﬁcial zones in both
normal and OA cartilage. In contrast, although in normal cartilage
the EphB4 receptor is also only localized at the superﬁcial zone,
during OA it is observed throughout the cartilage layers with
signiﬁcant (p<0.01) increase in both the superﬁcial and deep
zones. This coincides with a signiﬁcant increase in EphB4 receptor
gene expression level in OA compared to normal (p<0.0001).
Modulation experiments performed on OA chondrocytes showed
that the receptor is inhibited by IL-1β and TNF-α. Interestingly,
EphB4 activation signiﬁcantly inhibited the gene expression levels
of IL-1β, IL-6, MMP-1, MMP-9, MMP-13 and PAR-2, whereas
MMP-2 was unaffected. It signiﬁcantly increased collagen type II
α1 expression and also inhibited the IL-1β-stimulated effect on the
protein production of IL-6, MMP-1 and MMP-13. EphB4 receptor
activation signiﬁcantly reduced the PI3K/Akt pathway.
Conclusions: Our study is the ﬁrst to show the presence and role
of ephrin B2/EphB4 receptor in human OA chondrocytes. The data
support the notion that activation of the EphB4 receptor by ephrin
B2 positively impacts the abnormal metabolism of OA cartilage by
inhibiting important catabolic factors involved in this disease and
at the same time as increasing the anabolic activity. Thus, ephrin
B2 could act as a speciﬁc therapeutic approach in OA by acting
both on cartilage and subchondral bone.
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Purpose: Osteoarthritis (OA) is the most common human joint
disease. Recent studies suggest the involvement of osteoprote-
gerin (OPG), receptor activator of nuclear factor-κB (RANK) and
RANK ligand (RANKL) in the abnormal OA subchondral bone
metabolism; however, very few studies have looked at these fac-
tors in the articular chondrocytes or their functional consequences
on these cells. We investigated the expression of OPG, RANK and
RANKL on human chondrocytes comparing normal to OA, and the
modulation of their production by some catabolic factors. Further,
we evaluated on human OA chondrocytes the roles of OPG and
RANKL on the production of catabolic/anabolic factors involved in
this disease.
Methods: Gene expression level was determined using real-time
PCR. The protein production of RANK and RANKL were deter-
mined by ﬂow cytometry, and that of OPG by a speciﬁc ELISA.
Modulation of OPG, RANK and RANKL was determined upon
treatment with IL-1β, TNF-α, and PGE2. The functional conse-
quences were examined following treatment with either soluble
RANKL or OPG-Fc (OPG without the heparin binding domain) at
50 and 100 ng/ml, and the production of catabolic factors including
cytokines, MMPs and PAR-2, and the anabolic factor collagen type
II evaluated.
Results: OPG, RANK and RANKL were all expressed and pro-
duced by human chondrocytes. Interestingly, data showed that
membranous RANK was produced only by an OA chondrocyte
subpopulation (29%) which was localized throughout the carti-
lage. Compared to normal, the OPG/RANKL ratio was signiﬁ-
cantly (p=0.05) reduced on the OA chondrocytes, whereas the
RANK/RANKL ratio was signiﬁcantly (p<0.03) increased. Treat-
ment with catabolic factors showed that OPG production and
membranous RANKL levels were signiﬁcantly enhanced by IL-1β,
TNF-α, and PGE2, whereas membranous RANK was signiﬁcantly
increased only with IL-1β. Administration of soluble RANKL was
without effect on the OA chondrocytes. However, addition of OPG-
Fc signiﬁcantly stimulated MMP-13 (p=0.05) and PAR-2 (p<0.04)
production.
Conclusions: Our ﬁndings showed that human normal and OA
chondrocytes express and produce OPG, RANK, and RANKL.
OA chondrocyte treatment with catabolic factors had variable
effects on each member of the triad, but pointed to an increased
biological effect of OPG. Interestingly, OPG, but not RANK or
RANKL, appears to be involved in the progression of OA by
signiﬁcantly increasing two catabolic factors involved in cartilage
pathophysiology, MMP-13 and PAR-2.
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Purpose: Pitx1 is an essential transcription factor for development
and maintenance of bone and cartilage speciﬁcally in hindlimbs
and mandible. Knockout of Pitx1 gene in mouse led to a sever
abnormalities in morphogenesis of bone and cartilage tissues
whereas Pitx1+/- mice progressively developed with ageing de-
generative changes of the knee resembling human OA. These
observations prompted us to investigate the role of this tran-
scription factor in OA patients. We have discovered that Pitx1
mRNA and proteins were hardly expressed in human OA articular
chondrocytes and cartilage sections when compared to matched
control subjects. Recent results from our lab have also shown loss
of Pitx1 expression in osteoarthritic (OA) chondrocytes. To under-
stand the mechanism that leads to loss of Pitx1 expression in OA
chondrocytes we have investigated the transcriptional regulation
of this transcription factor in normal and OA chondrocytes.
Methods: Human Pitx1 promoter gene was cloned upstream of
a luciferase reporter gene. Using C28/I2 chondrocyte cell line,
we have identiﬁed important regions for Pitx1 gene regulation
using different complementary approaches (sequencing, mass
spectrometry, DNA pull-downs method, ChIP assay and transient
